These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20953915)

  • 1. Efficacy of pretreatment of allografts with methoxypolyethylene glycol-succinimidyl-propionic acid ester in combination with an anti-OX40L monoclonal antibody in relieving graft-versus-host disease in mice.
    Huang Y; Feng S; Tang R; Du B; Xu K; Pan X
    Int J Hematol; 2010 Nov; 92(4):609-16. PubMed ID: 20953915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylaxis of graft-versus-host disease in mice by chemical modification of graft and OX40-OX40L costimulatory pathway.].
    Huang YH; Feng SR; DU B; Xu KL; Pan XY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Nov; 30(11):735-40. PubMed ID: 20137307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
    Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.
    Xu K; Li C; Pan X; Du B
    Int J Hematol; 2007 Jul; 86(1):84-90. PubMed ID: 17675273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on control of graft-versus-host disease by blocking CD137-CD137L ligand costimulatory pathway in mice].
    Li CH; Xu KL; Pan XY; Du B
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):93-7. PubMed ID: 17650668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory T Cells Mediate Cardiac Allograft Vasculopathy and are Inactivated by Anti-OX40L Monoclonal Antibody.
    Wang H; Zhang Z; Tian W; Liu T; Han H; Garcia B; Li XC; Du C
    Cardiovasc Drugs Ther; 2014 Apr; 28(2):115-22. PubMed ID: 24254032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of reducing graft-versus-host disease by in vitro blockade of CD40-CD40 ligand co-stimulatory pathway in allogeneic bone marrow transplantation mouse model].
    Huang SL; Chen C; Duan LN; Li HW; Wen GM; Li L; Zhan MY; Wei J
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jun; 24(6):290-4. PubMed ID: 12859863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of chemical modification of grafts on the survival improvement post haploidentical bone marrow transplantation in mice].
    Yang G; Tang SQ; Zhang XF; Liu LZ; Huang DS; Wang JW
    Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):684-7. PubMed ID: 15482672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury.
    Panoskaltsis-Mortari A; Taylor PA; Rubin JS; Uren A; Welniak LA; Murphy WJ; Farrell CL; Lacey DL; Blazar BR
    Blood; 2000 Dec; 96(13):4350-6. PubMed ID: 11110712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade.
    Dai H; Peng F; Lin M; Xia J; Yu S; Lan G; Wang Y; Xie X; Fang C; Corbascio M; Qi Z; Peng L
    Transpl Immunol; 2015 Mar; 32(2):84-91. PubMed ID: 25613092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
    Blazar BR; Taylor PA; Smith S; Vallera DA
    Blood; 1995 Feb; 85(3):842-51. PubMed ID: 7833486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.